Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $188
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and raises the price target from $171 to $188.
March 20, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst David Amsellem maintains an Overweight rating on Jazz Pharmaceuticals and raises the price target from $171 to $188.
The increase in the price target by Piper Sandler, along with the maintenance of an Overweight rating, suggests a positive outlook on Jazz Pharmaceuticals' stock. This is likely to instill confidence in investors and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100